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Summary:  We developed and validated prognostic models, using data from 1699 HIV-uninfected and 
HIV-infected adults with tuberculous meningitis (TBM). The final models showed good performance, and 
could be used in clinical practice to identify TBM patients at high risk of death. 
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Abstract  
Background: Tuberculous meningitis (TBM) is the most severe form of extra-pulmonary tuberculosis. 
We developed and validated prognostic models for 9-month mortality in HIV-uninfected and HIV-
infected adults with TBM.  
Methods: We included 1699 subjects from four randomized clinical trials and one prospective 
observational study conducted at two major referral hospitals in Southern Vietnam from 2001-2015. 
Modelling was based on multivariable Cox proportional hazards regression. The final prognostic models 
were validated internally and temporally, and displayed using nomograms and a web-based app 
(https://thaole.shinyapps.io/tbmapp/).  
Results:  A total of 951 HIV-uninfected and 748 HIV-infected subjects with TBM were included, of whom 
219/951 (23.0%) and 384/748 (51.3%) died during 9-month follow-up. Common predictors for increased 
mortality in both populations were higher Medical Research Council (MRC) disease severity grade and 
lower cerebrospinal fluid lymphocyte cells count. In HIV-uninfected subjects, older age, previous 
tuberculosis, not receiving adjunctive dexamethasone, and focal neurological signs were additional risk 
factors; in HIV-infected subjects, lower weight, lower peripheral blood CD4 cell count, and abnormal 
plasma sodium were additional risk factors. The areas under the receiver operating characteristic curves 
(AUCs) for the final prognostic models were 0.77 (HIV-uninfected population) and 0.78 (HIV-infected 
population), demonstrating markedly better discrimination than the MRC grade (AUC 0.66 and 0.70) or 
the Glasgow Coma Score (AUC 0.68 and 0.71) alone. 
Conclusions: The developed models showed good performance and could be used in clinical practice to 
assist doctors in identifying TBM patients at high risk of death and at increased need of supportive care. 
Keywords: Tuberculous meningitis; prognostic models; mortality; HIV   
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Introduction 
Tuberculous meningitis (TBM) accounted for around 1-5% of the 10.4 million new tuberculosis cases in 
2015 and is the most severe manifestation of the disease, killing or disabling around half of all sufferers 
[1] . TBM is especially common in children and those infected with HIV, in whom outcomes are poor [2]. 
In a recent trial conducted in Vietnam, approximately 30% of the participants died during the 9-month 
study period and 40% of the survivors had disabilities [3].  
The British Medical Research Council (MRC) constructed the first TBM severity grades for use in the 
1948 trial of streptomycin [4]. Patients were sub-divided based on clinical experience rather than 
statistical derivation into ‘early’ (no clinical signs of meningitis or focal neurology and fully conscious), 
‘medium’ (patient’s condition falling between early and advanced) and ‘advanced’ (extremely ill, in deep 
coma).  With the introduction of the Glasgow coma score (GCS) in 1974, this was modified to: Grade I 
(GCS 15; no focal neurological signs), Grade II (GCS 11-14, or 15 with focal neurological signs) and Grade 
III (GCS≤10)[5].  This grading system has become the most widely used classification for TBM severity.  
Despite the age of the MRC scale, and its lack of statistical derivation, improved and robust prediction 
models for poor outcomes (mortality and/or neurological deficit) in TBM based on large cohort studies 
and rigorous statistical methodology are still lacking. Amongst prognostic studies in TBM published in 
the last 20 years, the majority were based on a small number of subjects (from 23 - 507), and modern 
prognostic modelling tools for handling missing data or model validation were rarely used [6–9]. 
The primary objective of this study was to develop and validate novel robust prognostic models for 9-
month mortality in adult TBM patients with and without HIV co-infection. The models were based on a 
large dataset of 1699 subjects (951 HIV-uninfected, 748 HIV-infected) enrolled in four randomized 
controlled trials and one prospective cohort study conducted in Vietnam. In addition, we compared the 
predictive performance of the developed models with the MRC grading system and the GCS, both widely 
used in the assessment of TBM severity. 
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Methods 
Study population  
Study participants: The study population comprised subjects enrolled in five TBM studies conducted 
between 2001 and 2015 at two tertiary referral centers in Ho Chi Minh City, Vietnam: Pham Ngoc Thach 
(PNT) Hospital and the Hospital for Tropical Disease (HTD) [3,10–13].  
Detailed descriptions of the studies have been published elsewhere [3,10–13] and are summarised in 
Supplementary Table 1. All studies were approved by the Oxford Tropical Research Ethics Committee, 
and the HTD and PNT Hospital Ethics Committees. 
Inclusion criteria: The inclusion criteria for the five studies are provided in Supplementary Table 1. In 
brief, all five studies included adult subjects with a clinical diagnosis of TBM defined as having more than 
5 days of meningitis symptoms, nuchal rigidity, and CSF abnormalities suggestive of TBM; additional 
criteria were radiological evidence of TB on chest X-ray or brain scan, or microbiological evidence of TB 
from specimens other than CSF.  Diagnostic categories of definite, probable, or possible TBM were 
defined according to study-specific diagnostic criteria as the uniform TBM case definition only became 
available in 2010 [14].  All study participants were included in the pooled analysis except if they had a 
confirmed alternative diagnosis, a study drug administration error, or an unknown HIV status.  
Laboratory investigation:  CSF specimens were stained and cultured by standard methods for pyogenic 
bacteria, mycobacteria, and fungi. In the last study [3], CSF was additionally tested with the Xpert 
MTB/RIF assay (Cepheid, California, USA). Isolates of M. tuberculosis were tested for susceptibility to 
isoniazid, rifampin, ethambutol, and streptomycin by the mycobacterial growth indicator tube method 
[15]. Baseline peripheral blood CD4 cell counts were measured for all HIV-infected adults by flow 
cytometry. 
Anti-tuberculosis and adjunctive treatment: Unless study participants were randomized to an 
experimental anti-tuberculosis treatment, participants received standard anti-tuberculosis regimen 
consisting of isoniazid (5mg/kg/day; maximum 300mg/day), rifampin (10mg/kg/day; maximum 
600mg/day), pyrazinamide (25mg/kg/day; maximum 2g/day) and ethambutol (20mg/kg/day; maximum 
1.2g/day) or streptomycin (20mg/kg/day; maximum 1g/day) for 3 months, followed by rifampin and 
isoniazid at the same doses for a further 6 months. Since 2005, all patients received adjunctive 
dexamethasone for the first 6-8 weeks of treatment [3].  
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Primary outcome 
The primary endpoint was overall survival during a 9-month follow-up period. Patients without 
documented death during the follow-up period were censored at 9 months or at the last date they were 
known to be alive, whichever was earlier.  
Candidate predictors 
Candidate predictors were initially selected based on clinical judgement, their status as established risk 
factors in previous publications [6–9,16–18], and completeness of the data. The number of predictors 
was further restricted based on a rule of thumb of requiring at least 10 events for each included 
predictor variable or degree of freedom [19]. The final list of candidate predictors is presented in 
Supplementary Table 2. For all laboratory parameters and radiology assessments, we used the value 
recorded closest to enrolment (up to ± 7 days from enrolment). Of note, CSF total white cell count and 
CSF total lymphocyte count were strongly correlated; therefore only CSF lymphocyte count was included 
as candidate predictor. Resistance is known to be an important independent predictor for mortality in 
subjects with TBM [20,21]. However, unless earlier isolates are available or rapid molecular tests 
performed, information about a patients’ TB drug susceptibility is not available at enrolment. The main 
models therefore did not include resistance but models with resistance were depicted in the 
supplementary material.  The cohort variable was included in the full model to represent the change in 
patient management, treatment, and standard of health care over the 15 years' time span of the 
included studies. 
We decided to construct separate prognostic models for the HIV-uninfected and HIV-infected TBM 
populations because they are clinically distinct populations, and we expected that predictors may differ 
between them.  
Statistical analysis  
Full details of the statistical analysis are described in Supplementary appendix S1. In brief, incomplete 
data were multiply imputed using multivariable imputation by chained equations (mice) [22]. The 
statistical model of choice was multivariable Cox proportional hazards regression including all pre-
specified candidate predictors. We tested for potential non-linear effects of continuous candidate 
predictors and for interactions, i.e. effect modifications, between age and other candidate predictors. 
Two variable selection methods were used to simplify the model: i) backwards stepwise selection with a 
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stopping rule based on Akaike's information criterion, and ii) the Least Absolute Shrinkage and Selection 
Operator (lasso) [23]. We combined model selection with bootstrapping and based the final models on 
the most frequently (≥ 60%) included variables across all imputed and bootstrap data sets [24]. We used 
the area under the cumulative/dynamic ROC curve (AUC) [25] for mortality prediction at 9 months to 
assess the discrimination of the models and calibration plots [26] to visually assess how closely the 
predicted mortalities agree with the observed mortalities. Internal bootstrap validation was performed 
to correct measures of model performance for over-fitting. In addition, we performed temporal 
validation where data from the most recent trial served as the test dataset to validate models that were 
developed based on earlier studies. The final prognostic models, i.e. the variable-selected models with 
the highest AUC, were implemented in a web based mortality calculator and graphically depicted using 
nomograms [26]. All analyses were conducted using R version 3.3.1 [27]. 
Results 
Baseline characteristics of study participants 
The five studies included a total of 1734 subjects, of which 1699 were included for prognostic modelling 
(Supplementary Figure 1). The reasons for excluding 35 subjects were a confirmed other diagnosis (n = 
16), unknown HIV status (n=16), or a study drug administration error (n = 3).  
Table 1 presents the baseline characteristics of all included subjects; 951 were HIV-uninfected (56.0%) 
and 748 (44.0%) were HIV-infected.  The median age was 34 years (inter-quartile range 27-45) and 823 
(48.4%) had definite, microbiologically confirmed TBM.  MRC grade was I in 588 (34.6%) subjects, II in 
743 (43.8%) subjects, and III in 367 (21.6%) subjects. Amongst HIV-infected subjects, the median CD4 
cell count was 41 cells/mm3, and 124 (16.6%) were on ART at baseline. Compared with HIV-uninfected 
subjects, those infected with HIV tended to be younger (median 31 vs. 40 years), were more frequently 
male (85.6% male vs. 62.3% male) and diagnosed with MRC grade III (25.6% vs. 18.5%).  
During 9-month follow-up, 219/951 (23.0%) HIV-uninfected and 384/748 (51.3%) HIV-infected subjects 
with TBM died. Amongst the 1096 survivors, 998 (91.1%) were followed up for at least 260 days.  Yearly 
recruitment into the five studies and observed mortality by HIV status are shown in Figure 1. The figure 
displays a decline in mortality over time, which is particularly pronounced in HIV-infected subjects. In 
this sub-population, the estimated 9-month mortality dropped from 52-92% during 2001-2007 to 35-
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50% during 2011-2015. Coincidently, the number of study participant on ART at enrolment in the first 
period was only 7/407 (1.7%), and increased to 117/341 (34.3%) in the second period.  
Prognostic models  
Univariable analyses of the effect of all candidate predictors for survival are shown in Supplementary 
Tables 3 and 4. Results of the multivariable analyses are shown in Table 2 and Supplementary Table 5. 
The final models identified a higher Medical Research Council (MRC) disease severity grade and lower 
cerebrospinal fluid lymphocyte cell counts as risk factors for mortality in both HIV-uninfected and  HIV-
infected subjects (Table 2). Importantly, the mortality rate in MRC grade III (GCS≤10) was three-fold 
higher in HIV-uninfected patients and four-fold higher in HIV-infected patients compared to MRC grade I 
(GCS 15; no focal neurological signs). Mortality for MRC grade II (GCS 11-14, or 15 with focal 
neurological signs) was intermediate in both populations. 
In HIV-uninfected subjects, older age, previous tuberculosis, not receiving adjunctive dexamethasone, 
and focal neurological signs were additional predictors of higher mortality. Of note, the mortality rate 
was increased by more than 50% in patients with previous tuberculosis and those with focal 
neurological signs, and almost doubled for patients who did not receive dexamethasone.     
In the HIV-infected population, lower weight, lower peripheral blood CD4 cell count, and abnormal 
plasma sodium were additional predictors of higher mortality. Plasma sodium had a significant non-
linear association with survival, and both decreased and elevated sodium values were associated with a 
higher predicted mortality compared to intermediate value. Ongoing ART therapy at enrolment was 
associated with a more favourable outcome in univariable analysis (Supplementary Table 4), but was no 
longer significantly associated with survival after adjusting for other factors.  
There was no clear evidence that age modified the effect of any of the other predictors (p-value for 
overall interaction test of 0.14 in HIV-uninfected, and of 0.10 in HIV-infected subjects).  
 
Model validation 
The final models showed good discrimination between TBM survivors and deaths at 9 months; the 
corresponding AUCs in internal validation (corrected for over-fitting) were 0.77 in the HIV-uninfected 
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population and 0.78 in the HIV-infected population, respectively (Table 3). The addition of drug 
resistance as a covariate resulted in only a slightly improved model discrimination with AUC values 
ranging from 0.77–0.79 (Supplementary Table 7). 
In internal validation, the models showed good agreement between predicted and observed mortality 
(Supplementary Figures 2a and 2c). In temporal validation, calibration in the HIV-uninfected groups 
remained satisfactory whereas in the HIV infected group, models developed on earlier studies 
systematically overestimated the actual mortality in the most recent trial (Supplementary Figures 2b and 
2d).  
Figure 2 shows predicted survival curves of the final simplified models in four risk groups defined using 
cut-off points at the 16th, 50th, 84th percentiles of the prognostic index generated by these models [28]. 
They show strong prognostic separation across risk strata, good agreement between predicted survival 
curves and Kaplan-Meier estimates in the full dataset, and mild to substantial risk overestimation in 
temporal validation in HIV-uninfected and HIV-infected subjects 
Comparison of prognostic models with MRC grade and GCS alone 
MRC grade and GCS predicted mortality similarly well (AUC ranging from 0.66-0.71) (Table 3). The 
corresponding ROC curves for the MRC grade, GCS and the final models are shown in Figure 3. MRC 
grade and GCS were both clearly inferior to the developed multivariable models in terms of 
discrimination (p-values for tests of equality between AUC values <0.001 for all comparisons) whereas 
discrimination did not differ significantly between MRC grade and GCS (p-value = 0.23 in HIV uninfected 
and p-value = 0.19 in HIV infected).  
 
Nomograms and web app for mortality prediction 
Figure 4 visualizes the final models as nomograms. For clinical use, this model has also been 
implemented as a user-friendly web app available at https://thaole.shinyapps.io/tbmapp/ . We also 
generated nomograms for use when resistance information is available (Supplementary Figure 3). Of 
note, for creation of the nomogram and the web app in the HIV-infected population, the cohort variable 
was chosen as our most recent trial [3] since this is most relevant for future prediction.  
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Discussion 
We developed and validated prognostic models for 9-month mortality after TBM diagnosis in a large 
dataset of 951 HIV-uninfected and 748 HIV-infected TBM patients. We found that a higher MRC grade 
and lower CSF lymphocyte cell counts were predictors for mortality in both groups. MRC grade assesses 
the severity of neurological impairment and numerous studies have shown its strong association with 
poor outcome [29,30].   The predictive value of lower CSF lymphocyte counts is intriguing. Others have 
recently found higher CSF neutrophils predicted death from TBM [31] ; both findings reflect the poorly 
understood importance of neuro-inflammation to outcome from TBM.   
Additional risk factors in HIV-uninfected patients were older age, previous TB treatment, not receiving 
dexamethasone, and having focal neurological signs. In HIV-infected subjects, additional risk factors for 
mortality were lower weight, lower CD4 cell count, and abnormal plasma sodium level. These finding are 
consistent with results from previous published studied conducted in India [32], Hong Kong [17], Taiwan 
[8], Turkey [33], South Africa [34], and Brazil [35]. The inclusion of different predictors in the two HIV 
populations may suggest important differences in disease pathogenesis and outcomes in these two 
subgroups.  
The main analysis did not include drug-resistance as a covariate because this information is often not 
available at enrolment. Alternative models including drug resistance showed only relatively little 
improvement in model performance, especially in HIV-uninfected subjects.  However, we note the low 
prevalence of multidrug resistant TB (MDR-TB), an important predictor of poor outcome in TBM [20,21], 
in our cohort which may have contributed to this finding.  
The final prediction models were carefully developed and validated with proper statistical methods [36]. 
They showed good discrimination between TBM-survivors and deaths in both internal and temporal 
validation, and substantially improved over the MRC grade or the GCS alone. Although our models had 
excellent calibration in internal validation, they over-estimated mortality in temporal validation where 
the model was developed on earlier studies and tested on subjects included in the most recent trial. This 
overestimation was mild in HIV-uninfected subjects but substantial in HIV-infected subjects. It may be 
explained by improvements in treatment, especially the availability of ART, and patients' supportive care 
over time.  Importantly, because ART only became widely available in Vietnam in 2005 [37] and being on 
ART was an exclusion criterion for the ART timing trial, the intensified treatment trial [3] was the only 
study that included subjects on ART at TBM diagnosis. Therefore, the effect of ART was neglected in the 
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temporal validation, and this may have contributed to the observed overestimation. Temporal 
heterogeneity was addressed by including the cohort as a covariate in the statistical regression models.  
Survival for future patients is anticipated to be close to predictions adjusted to our most recent study. 
Our study has several limitations, mostly owing to the characteristics of our database. Firstly, CSF 
lactate, which may be an important risk factor [38], was not taken into account in our final model 
because it was missing in >40% of subjects. Secondly, previous studies suggested that leukotriene A4 
hydrolase (LTA4H) genotype is a determinant of the inflammatory response in HIV-uninfected adults 
with TBM, and consequently might predict who benefits from adjunctive corticosteroid treatment[39]. 
This factor, therefore, might have an influence on survival of HIV-uninfected TBM subjects. As the 
information of LTA4H genotype was not available for all included studies, we did not consider this 
covariate in our analyses. Thirdly, the models were developed and validated based on data from two 
large hospitals in Southern Vietnam only. Thus, it would be desirable to validate and possibly improve 
our models in an independent external database. Finally, our models only included risk factors available 
at TBM diagnosis. However, changes in biomarkers that are repeatedly measured during the disease 
course may carry important information which could allow updating and improving an initial prognosis 
during TB treatment. The value of such longitudinally measured biomarkers will be examined in a future 
research project.  
Our final models were displayed as nomograms and implemented in a user friendly web based risk 
calculator (https://thaole.shinyapps.io/tbmapp/) for use in clinical practice to improve prognostic 
stratification in TBM patients. Patients at high risks could be identified early and then put on stricter 
monitoring schemes to receive appropriate counselling/supportive care, or enrolled in future clinical 
trials that explore novel treatments targeted to severe TBM. 
Our models are based on one of the largest sources of prospectively collected clinical data for TBM 
disease worldwide. The final prognostic models included variables which are usually available for 
patients with TBM. Overall, our prediction models have good discrimination and calibration 
performance, and clearly outperformed the MRC grading score. 
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Table 1: Baseline characteristics of patients included in the pooled database, overall and by HIV status 
Characteristic All TBM patients  
(N=1699) 
 
HIV-uninfected TBM  
(N=951) 
 
HIV-infected TBM  
(N=748) 
 
n 
Summary  
statistic 
 n 
Summary 
 statistic 
 n 
Summary 
 statistic 
 
Cohort 1699   951   748   
- Dexamethasone trial  534(31.4%)   436(45.9%)   98(13.1%)  
- Fluoroquinolone  trial  56(3.3%)   53(5.6%)   3(0.4%)  
- TBM HIV cohort  58(3.4%)   0(0%)   58(7.7%)  
- ART timing trial  248(14.6%)   0(0%)   248(33.2%)  
- Intensified treatment trial  803(47.3%)   462(48.6%)   341(45.6%)  
Age [years] 1698 34(27,45)  951 40(27,56)  747 31(26,35)  
Sex: Female 1699 514(30.25%)  951 406(42.7%)  748 108(14.4%)  
Weight [kg] 1695 46(41,51)  951 46(42,52)  744 45(40,50)  
Dexamethasone treatment: Yes  1699 1436(84.5%)  951 742(78.0%)  748 694(92.8 %)  
On ART at enrolment: Yes 745 124(16.6%)  - -  745 124(16.6%)  
MRC Grade § 1698   951   747   
- MRC Grade I  588(34.6%)   327(34.4%)   261(34.9%)  
- MRC Grade II  743(43.8%)   448(47.1%)   295(39.5%)  
- MRC Grade III  367(21.6%)   176(18.5%)   191(25.6%)  
Illness duration at study entry  [days] 1685 15(10,30)  948 15(10,26)  737 15(9,30)  
Previous TB treatment: Yes 1658 236(14.2%)  922 88(9.5%)  736 148(20.1%)  
Focal neurological signs: Yes 1683 818(48.6%)  951 517(54.4%)  732 301(41.1%)  
Temperature [degrees Celsius] 1697 37.6(37.2,38.5)  950 37.7(37.2,38.5)  747 37.5(37.2,38.5)  
Convulsions: Yes 1685 50(3.0%)  950 25(2.6%)  735 25(3.4%)  
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Plasma sodium [mmol/l] 1537 129(124,133)  843 130(125,134)  694 127(123,132)  
CSF lymphocyte count [cells/ mm
3
] 1614 85(27.6,197.5)  919 94(32.5,200)  695 73 (23.3,188.8)  
CSF protein [g/l] 1624 1.3(0.70,1.94)  909 1.2 (0.7,2.0)  715 1.3(0.7,1.9)  
CSF glucose [mmol/l] 1636 1.60(1.05,2.30)  920 1.52(1.00,2.30)  716 1.70(1.17,2.33)  
Ratio of CSF glucose and blood glucose 1470 0.30(0.21,0.41)  830 0.30(0.20,0.40)  640 0.30(0.21,0.42)  
Microbiologically confirmed/definite 
TBM 
1699 823(48.4%)  951 361(38.0%)  748 462(61.8%)  
Resistance £ 1699   951   748   
- No isoniazid or rifampin resistance   479(28.2%)   203(21.4%)   276(36.9%)  
- Isoniazid monoresistance   172(10.1%)   63(6.6%)   109(14.6%)  
- Rifampin monoresistance /MDR  35(2.1%)   10(1.1%)   25(3.3%)  
- Unknown resistance   1013(59.6%)   675(71.0%)   338(45.2%)  
Chest x-ray miliary TB: Yes 1525 279(18.3%)  890 165(18.5%)  635 114(17.9%)  
Peripheral blood CD4 count 
[cells/mm
3
] 
646 41 (16,108)  - -  646 41(16,108)  
          
Summary statistics are frequency (%) for categorical variables and median (interquartile range, IQR) for continuous variables. n refers to the number of 
subjects with non-missing data for the respective characteristic. 
£: Isoniazid monoresistance is defined as resistance to isoniazid but not to rifampin. Multidrug resistance (MDR) is defined as resistance to at least isoniazid 
and rifampin. Unknown resistance is defined as drug-susceptibility test results not available. In all categories, resistance to other drugs may be present. 
§ MRC Grade I (GCS 15; no focal neurological signs); MRC Grade II (GCS 11-14, or 15 with focal neurological signs); MRC Grade III (GCS≤10)).  
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Table 2: Final Cox regression models for 9-month survival in each HIV population. Estimates were pooled across multiply imputed datasets. 
Variable 
HIV-uninfected TBM population  HIV-infected TBM population 
Full model  
Final model  
(Model selected by the lasso) 
 Full model  
Final model  
(Model selected by stepwise 
backwards model selection) 
HR 95% CI 
p-
value 
 HR 95% CI 
p-
value 
 HR 95% CI 
p-
value 
 HR 95% CI p-value 
Age [per +10 years] 1.24 1.15 - 1.34 <0.001  1.24 1.15 - 1.34 <0.001  0.99 0.85 - 1.16 0.89     
Sex: male 1.07 0.79 - 1.44 0.67      0.95 0.70 - 1.30 0.77     
Weight [per +10 kgs] 0.88 0.73 - 1.06 0.17      0.72 0.61 - 0.85 <0.001  0.73 0.63 - 0.85 <0.001 
MRC Grade §                
- MRC Grade I 1    1    1    1   
- MRC Grade II 1.36 0.87 - 2.13 0.17  1.41 0.9 - 2.19 0.13  1.71 1.24 - 2.35 0.001  1.88 1.43 - 2.48 <0.001 
- MRC Grade III 2.97 1.83 - 4.83 <0.001  3.05 1.92 - 4.86 <0.001  3.76 2.69 - 5.26 <0.001  4.08 3.07 - 5.41 <0.001 
Illness duration at study 
entry   [days] ‡ 
1.03 0.91 - 1.17 0.61 
     
1.02 0.93 - 1.11 0.73 
    
Previous TB treatment   : Yes 1.46 1.00 - 2.13 0.05  1.57 1.09 - 2.26 0.015  1.26 0.97 - 1.65 0.09     
Focal neurological signs: Yes 1.80 1.22 - 2.64 0.003  1.65 1.15 - 2.39 0.007  1.15 0.87 - 1.53 0.33     
Temperature[Celsius] 0.96 0.79 - 1.17 0.71      1.09 0.96 - 1.24 0.18     
Convulsion: Yes 0.96 0.41 - 2.22 0.92      0.95 0.58 - 1.56 0.83     
Dexamethasone: No 1.67 1.15 - 2.40 0.006  1.97 1.46 - 2.67 <0.001  1.12 0.68 - 1.85 0.65     
Plasma sodium [per +10 
mmol/l] £ 
1.01 0.85 - 1.21 0.89 
       <0.001     <0.001 
- 135 vs. 125 1.01 0.85 - 1.21       1.09 0.91 - 1.31   1.07 0.90 - 1.28  
- 115 vs. 125 0.99 0.83 - 1.17       1.63 1.31 - 2.04   1.06 1.29 - 2.00  
CSF lymphocyte count [cells/ 
mm
3
] ‡ 
0.88 0.82 - 0.94 <0.001 
 
0.86 0.81 - 0.92 <0.001 
 
0.93 0.87 - 0.99 0.017 
 
0.93 0.88 - 0.98 0.004 
CSF protein [g/l] ‡ 0.95 0.84 - 1.07 0.38      0.95 0.85 - 1.06 0.37     
CSF glucose [mmol/l] 1.03 0.87 - 1.23 0.70      1.08 0.98 - 1.19 0.10     
Ratio of CSF glucose and  
blood glucose ‡  
1.02 0.81 - 1.28 0.88 
     
0.91 0.77 - 1.08 0.30 
    
Chest x-ray miliary TB: Yes 0.82 0.56 - 1.18 0.29      0.95 0.70 - 1.29 0.73     
Peripheral blood CD4 
[cells/mm
3
] ‡ 
- - -      
0.91 0.85 - 0.98 0.012 
 
0.9 0.84 - 0.96 0.002 
On ART at enrolment [Yes] - - -      0.87 0.60 - 1.26 0.45     
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Cohort                
- Intensified trial 1        1    1   
- Dexamethasone trial 1.46 0.94 - 2.27 0.09      1.96 1.23 - 3.14 0.005  1.72 1.25 - 2.37 <0.001 
- Fluoroquinolone trial 1.12 0.51 - 2.46 0.77             
- TBM HIV cohort         2.58 1.63 - 4.06 <0.001  2.64 1.81 - 3.84 <0.001 
- ART timing trial         1.78 1.28 - 2.47 <0.001  1.71 1.34 - 2.19 <0.001 
HR=hazard ratio, CI=confidence interval. 95% CI and p-value for final models do not take into account the uncertainty of model selection. 
‡HR per 2-fold increase.  
£ In HIV-infected subjects, the effect of sodium on mortality was significantly non-linear and modelled with a restricted cubic spline function with 2 degrees of 
freedom. To simplify interpretation of the corresponding regression coefficients, only HRs for two derived sodium contrasts from that model are given. P-
values for sodium In the HIV-infected population are based on overall Wald-tests of the restricted cubic spline function 
§ MRC Grade I (GCS 15; no focal neurological signs); MRC Grade II (GCS 11-14, or 15 with focal neurological signs); MRC Grade III (GCS≤10)).  
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Table 3: Discrimination of candidate models for TBM mortality by HIV population measured by the area under the cumulative/dynamic ROC curve (AUC) at 9-
months. 
Model Internal validation  Temporal validation 
Apparent AUC  
(95% CI)* 
Optimism  
Corrected AUC ‡ 
 AUC (95% CI) 
HIV-uninfected population  
Full model 0.79 (0.76-0.83) 0.76   0.77 (0.72-0.83) 
Model selected by stepwise backwards model 
selection 
0.78 (0.74-0.81) 0.76   
0.77 (0.71-0.82) 
Model selected by the lasso method ** 0.78 (0.75-0.82) 0.77   0.82 (0.77-0.87) 
MRC Grade § 0.66 (0.62-0.70) 0.66   0.70 (0.64-0.75) 
GCS 0.68 (0.64-0.72) 0.68   0.68 (0.62-0.75) 
HIV-infected population 
Full model 0.79 (0.75-0.83) 0.77   0.76 (0.70-0.82) 
Model selected by stepwise backwards model 
selection ** 
0.79 (0.75-0.82) 0.78   
0.73 (0.67-0.79) 
Model selected by the lasso method 0.78 (0.74-0.82) 0.77   0.75 (0.69-0.81) 
MRC Grade § 0.70 (0.66-0.74) 0.70   0.69 (0.63-0.75) 
GCS 0.71 (0.67-0.75) 0.71   0.68 (0.62-0.74) 
CI: confidence interval  
*Refers to performance estimated directly from the original 45 imputed datasets that were used to develop the prediction models. 
‡ Adjusted performance corrected for over-optimism through internal bootstrap validation. 
** Final simplified model. 
§ MRC Grade I (GCS 15; no focal neurological signs); MRC Grade II (GCS 11-14, or 15 with focal neurological signs); MRC Grade III (GCS≤10)).  
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Figure legends 
Figure 1:  Annual recruitment into the five contributing studies by HIV status. The black lines show estimated 9-month mortality (in %) 
for each calendar year based on the Kaplan-Meier method. 
Figure 2: Comparison between predicted survival of the final models and observed Kaplan-Meier estimates. Risk groups are defined using 
cut-points at the 16th, 50th, 84th percentiles of the prognostic index as generated by the final models (defining “good”, “fairly good”, “fairly 
poor”, and “poor” prognostic subgroups).  
Figure 3: Cumulative/dynamic ROC curves (apparent estimate) for mortality evaluated at 9 months for the final prognostic model, GCS, 
and MRC Grade in the HIV-uninfected and HIV-infected TBM populations. MRC Grade I (GCS 15; no focal neurological signs); MRC Grade II 
(GCS 11-14, or 15 with focal neurological signs); MRC Grade III (GCS≤10)).   
Figure 4: Nomograms for the prediction of 9-month mortality based on the final prognostic models for the HIV-uninfected and HIV-
infected TBM populations, respectively. To derive a prediction, locate the value of each predictor on the corresponding variable line, read 
the corresponding points assigned on the 0-100 scale and sum all of these points to a total point score. Then read the result on the Total 
Points scale and its corresponding prediction below. For HIV-infected nomogram, the cohort variable was chosen as the most recent trial 
[3] since this is most relevant for future prediction.  
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